Research advances of novel biologic therapeutic agents for lupus nephritis

Lupus nephritis (LN) is a common and serious complication of systemic lupus erythematosus (SLE). Current treatment of LN is based largely upon hormones and immunosuppressants associated with such adverse effects as easy relapse and easy infection. In recent years, researchers have identified a variety of biologic agents capable of enhancing the efficacy of traditional treatment regimens while minimizing drug side effects. This review summarized the latest researches of novel biologic therapeutic agents for LN.